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Background: Clinical observations have demonstrated that high levels of circulating insulin-like growth factor
binding protein-1 (IGFBP-1) are associated with type 1 diabetes (T1D), whereas low serum IGFBP-1 levels are
associated with the risk of type 2 diabetes (T2D). Recently, we reported that increased DNA methylation levels in
the IGFBP1 gene were associated with T2D. In the present study, we evaluated the epigenetic changes of IGFBP1 in
T1D and diabetic nephropathy (DN).
Results: In total, 778 Swedish individuals, including T1D patients with or without DN and subjects with the normal
glucose tolerance (NGT), were involved in the study. IGFBP1 methylation levels in genomic DNA extracted from
peripheral blood were analyzed with bisulfite pyrosequencing. Serum IGFBP-1 levels were measured with
radioimmunoassay. We found that DNA methylation levels in the IGFBP1 gene were decreased (15.6% versus 16.9%;
P < 0.001), whereas serum IGFBP-1 levels were increased (31 versus 24 μg/L, P = 0.003) in T1D patients compared
with NGT subjects. Furthermore, T1D patients with DN had increased circulating IGFBP-1 concentration compared
with the patients without DN (52 versus 28 μg/L; P = 0.006). However, no difference of the IGFBP1 DNA methylation
levels between T1D patients with and without DN was observed.
Conclusions: This study shows for the first time that T1D patients had decreased DNA methylation levels in the
IGFBP1 gene and further implies that increased circulating IGFBP-1 levels are associated with T1D and DN.
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Type 1 diabetes (T1D) is an autoimmune disorder char-
acterized by the absence of insulin production, and the
patients with T1D require insulin therapy to sustain life.
T1D is the most common type of diabetes among children
and young adults, but its onset can occur at any age [1].
T1D patients usually develop complications gradually over
the years. Diabetic nephropathy (DN) is one of the most
common microvascular complications of diabetes, affect-
ing approximately 40% of individuals with type 1 diabetes
[2]. The patients with DN usually start with microalbumi-
nuria and then develop persistent proteinuria, hyperten-
sion and declined kidney function. T1D and related DN
are complex diseases that result from the combination of* Correspondence: tianwei.gu@ki.se
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unless otherwise stated.genetic and nongenetic factors. In recent years, epigenetic
modifications were considered to be involved in the
pathogenesis of diabetes and diabetic complications [3-5].
DNA methylation changes are involved in epigenetic regu-
lation mechanisms, which allow alteration of gene func-
tion without mutating the sequence. DNA methylation
analyses can be performed in the scales of global genome
or specific gene regions and in the material of peripheral
blood with mixed cell types, particular cell types, or in tar-
get tissues [6-8]. Dick et al. [9] recently used both ap-
proaches of whole-blood DNA methylation profiling and
adipose tissue-specific methylation analysis for study of
epigenetic changes related to body mass index (BMI) and
suggested that the analysis of blood DNA methylation is
worthwhile and can reflect changes in relevant tissues for
a phenotype [9].
Circulating insulin-like growth factor binding protein-1
(IGFBP-1) is produced in the liver and is regulated mainlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tors (IGF-I and IGF-II), acts as a shuttle of IGFs to target
tissues, and regulates the activity of free IGF-I [10].
IGFBP-1 is considered to be the principal acute regulator
of IGF-I bioactivity and plays an important role in the de-
velopment of diabetes and complications [11]. Clinical in-
vestigations have demonstrated that low circulating levels
of IGFBP-1 are associated with type 2 diabetes (T2D)
[12-14], whereas high serum IGFBP-1 levels are associated
with T1D [15,16]. Furthermore, serum IGFBP-1 levels are
found to be increased in T1D patients with microalbumi-
nuria [17]. According to our previous study in Swedish
middle-aged and elderly twins, heredity estimates were
only 36% for serum IGFBP-1 levels, which implied that
nongenetic factors may contribute to the varied IGFBP-1
levels in diabetes [18]. IGFBP1 gene is located on chromo-
some 7p12.3, and a CpG island resides at the promoter
and 5′-UTR region in this gene. We recently reported that
increased DNA methylation levels are associated with
T2D in a Swedish population [19]. In this study, we fur-
ther analyzed DNA methylation changes of IGFBP1 in
Swedish T1D patients with and without DN and aimed
to evaluate the epigenetic changes of this gene in T1D
and DN.
Results
IGFBP1 DNA methylation changes and serum protein
variation between NGT and T1D
We analyzed DNA methylation levels at six CpG sites
(referred to as P1 to P6) of the IGFBP1 gene and found
that the IGFBP1 DNA methylation levels at five of the six
CpG sites were significantly decreased in T1D patients
(P1, 16.8%; P2, 14.4%; P3, 11.1%; P4, 11.9%; P6, 19.4%),
compared with those in NGT subjects (P1, 17.7%; P2,
15.6%; P3, 12.7%; P4, 13.8%; P6, 22.2%; P = 0.004 for
P1, P < 0.001 for P2, P3, P4, P6), except at P5 (19.7% inFigure 1 IGFBP1 DNA methylation changes and serum protein variati
diabetes. (A) The mean levels of IGFBP1 DNA methylation in T1D patients
16.9%; P < 0.001, adjusted for age). (B) IGFBP-1 serum levels in T1D patients
24 μg/L; P = 0.005).T1D versus 19.5% in NGT; P = 0.186). Combining all six
CpG sites, the mean levels of IGFBP1 DNA methylation
in T1D patients were significantly lower than those in
NGT subjects (15.6% versus 16.9%; P < 0.001, Figure 1A).
On the contrary, IGFBP-1 serum levels in T1D patients
were increased compared with those in subjects with NGT
(31 μg/L versus 24 μg/L; P = 0.005, Figure 1B).
We also analyzed the relation of IGFBP1 DNA methy-
lation levels with ages and circulating IGFBP-1 levels. A
positive correlation was found between IGFBP1 DNA
methylation levels and ages in T1D patients (r = 0.449;
P < 0.001) (Figure 2). Similarly, a correlation was seen
between IGFBP1 DNA methylation levels and duration
of diabetes in T1D patients (r = 0.240; P < 0.001) and
T1D patients with or without DN (r = 0.580 and 0.425;
P < 0.001 for both). Based on this observation, the com-
parison analyses of IGFBP1 DNA methylation levels and
P values, as described earlier, were adjusted by ages. How-
ever, no correlation was found between IGFBP1 DNA
methylation and circulating IGFBP-1 levels in T1D patients
with or without DN.
IGFBP1 DNA methylation changes and serum protein
variation between T1D with and without DN
We further analyzed IGFBP1 DNA methylation changes
and serum protein levels in T1D patients with and with-
out DN. No difference appeared in IGFBP1 DNA methy-
lation levels between T1D with and without DN in either
males (16.4% versus 15.4%, P = 0.186; Figure 3A) or fe-
male patients (15.9% versus 15.6%; P = 0.604; Figure 3B).
Compared with T1D patients without DN, however, the
IGFBP-1 serum levels in T1D patients with DN were sig-
nificantly increased in both male (52 μg/L versus 28 μg/l,
P = 0.021, Figure 3C) and female patients (71 μg/L versus
33 μg/L; P = 0.003; Figure 3D). Furthermore, no difference
of serum IGFBP-1 levels was found between male andon in Swedish men with normal glucose tolerance and type 1
were significantly lower than those in NGT subjects (15.6% versus
were increased compared with subjects with NGT (31 μg/L versus
Figure 2 Correlation of IGFBP1 DNA methylation levels with ages in Swedish type 1 diabetes patients. A positive correlation appeared
between IGFBP1 DNA methylation levels and ages in T1D patients (r = 0.449; P < 0.001).
Figure 3 IGFBP1 DNA methylation changes and serum protein variation in Swedish type 1 diabetes patients with and without diabetic
nephropathy. A and B demonstrated the similar IGFBP1 DNA methylation levels between T1D with and without DN in either male (16.4% versus
15.4%; P = 0.186 adjusted for age) or female patients (15.9% versus 15.6%, P = 0.604, adjusted for age). C and D indicate that the IGFBP-1 serum
levels in T1D patients with DN were significantly increased in both male (52 μg/L versus 28 μg/L; P = 0.021) and female patients (71 μg/L versus
33 μg/L; P = 0.003), in comparison with T1D patients without DN.
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P = 0.17) or the patients without DN (28 μg/L versus
33 μg/L; P = 0.28).
IGFBP1 DNA methylation changes and serum protein
variation according to BMI
We recently demonstrated that IGFBP1 DNA methyla-
tion changes are not dependent on BMI in T2D [19]. To
evaluate whether IGFBP1 DNA methylation changes and
serum protein levels were dependent on BMI in T1D,
we divided all T1D patients into four groups according
to BMI (that is, low-weight group (BMI < 18.5 kg/m2),
normal-weight group (18.5 to 25.0 kg/m2), overweight
group (25.0 to 30.0 kg/m2), and obese group (≥ 30.0 kg/
m2). We found that circulating IGFBP-1 levels were de-
creased gradually according to BMI (51, 39, 30, and
28 μg/L; P = 0.012). However, the IGFBP1 DNA methyla-
tion levels were similar among the four groups (16.0%,
15.9%, 15.6%, and 16.0%; P = 0.867).
Discussion
We conducted an epigenetic study of the IGFBP1 gene
in a Swedish cohort and demonstrated that IGFBP1
DNA methylation levels are decreased in T1D patients
compared with NGT subjects. The findings in the
present study together with our recent report [19] are
summarized in Table 1 and showed that increased and
decreased IGFBP1 DNA methylation levels are associated
with T2D and T1D, respectively, implying that IGFBP1
may confer different epigenetic effects in T1D and T2D.
Both T1D and T2D are characterized by hyperglycemia,
but the underlying pathogenic mechanisms are different.
T1D develops on the basis of autoimmune destruction of
pancreatic beta cells, which results in insulin deficiency,
whereas the hyperglycemia in T2D results from a combin-
ation of impaired insulin secretion and insulin resistance.
Although our studies have provided the evidence that
IGFBP1 has different DNA methylation levels in T1D
and T2D, the molecular mechanism is still unknown. In
this study, serum levels of IGFBP-1 in T1D are increased
compared with those in NGT subjects, which is consist-
ent with a previous report [15]. The hepatic production
of IGFBP-1 protein is regulated mainly by insulin [20].
Therefore, the reduction of IGFBP-1 in T1D is thoughtTable 1 A summary of the IGFBP1 DNA methylation and IGFB
erance, type 1 and type 2 diabetes
Group Number IGFBP1 DNA methylation levels (%) P value
T2D 164 20.0 (19.5-20.5) P < 0.001
NGT 242 16.9 (16.4-17.1) -
T1D 304 15.6 (15.1-16.1) P < 0.001
Data are presented as means (95% CI). NGT, normal glucose tolerance; T1D, type 1
versus T1D or T2D and adjusted for age.to be caused by the insulin deficiency in the patients, al-
though in T2D patients with short duration, the decreased
IGFBP-1 concentrations are mainly due to hyperinsuline-
mia. Thus, we hypothesized that the difference of IGFBP1
DNA methylation levels between T1D and T2D may be
related to insulin activity.
DNA methylation levels are known to be affected by
age and gender in healthy and disease conditions. The
significant interindividual differences in peripheral blood
DNA methylation have been discovered in longitudinal
studies, with both increase and decrease of the global
genome methylation/specific gene methylation in aging
[21,22]. In our recent report, age-matched NGT subjects
and T2D patients were included, and the range of their
ages was limited [19]. In the present study, we found a
positive relation between IGFBP1 DNA methylation levels
and ages in T1D patients. Although similar correlation be-
tween IGFBP1 DNA methylation levels and T1D duration
was observed, the onset of T1D occurred mainly in child-
hood, so we believe this correlation was affected mainly by
age. The mechanism behind the IGFBP1 DNA methyla-
tion with aging is still unknown. Aging-related insulin
resistance in T1D could be one of the explanations. In
addition, Benbassat et al. [23] showed that serum IGFBP-1
levels were slightly increased throughout adulthood. How-
ever, we could not find any correlation between serum
IGFBP-1 levels and ages in T1D patients.
In the present study, we showed that both male and
female patients with DN had increased IGFBP-1 serum
levels compared with those without DN. Flyvbjerg et al.
[24] previously conducted experiments with diabetic rats
and demonstrated that kidney accumulation of IGF-1 is
associated with kidney hypertrophy, which is an early
feature of DN. The increased circulating IGFBP-1 allows
trapping IGF-1 accumulated in kidneys and may conse-
quently contribute to the development of DN.
Consistent with our recent report of IGFBP1 DNA
methylation changes in T2D [19], data from the present
study imply that IGFBP1 DNA methylation levels are not
dependent on BMI. Furthermore, no correlation between
IGFBP1 DNA methylation changes and serum IGFBP-1
levels were observed. Several reasons may be included in
the explanation. First, multiple regulators exist for IGFBP-1
circulating levels, including stimulators such as glucagon,P-1 serum levels in Swedish men with normal glucose tol-
IGFBP-1 serum levels (μg/L) P value Reference
18 (16-20) 0.014 Gu T et al. 2013 [19]
24 (21–26) -
31 (28–35) 0.007 Present study
diabetes; T2D, type 2 diabetes; P values were from comparison tests of NGT
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amino acids [10,20,25,26]. Second, DNA samples used for
methylation analyses were extracted from peripheral blood
cells. A limitation in the present study is that we are un-
able to perform liver tissue-specific methylation analysis
in T1D patients and NGT subjects. Third, DNA methyla-
tion changes may affect mRNA transcription directly, but
not the protein-synthesis process. Although a recent study
indicated that DNA methylation analysis with whole-
blood samples can be used to reflect the changes in rele-
vant tissues [9], it may be interesting to investigate DNA
methylation and mRNA expression levels of the IGFBP1
gene in liver, in order to better understand the correlation
between DNA methylation changes and serum protein
levels.
Conclusion
In conclusion, this study demonstrates for the first time
that the decreased IGFBP1 DNA methylation levels are
associated with T1D but not with DN and contributes
further information that increased circulating IGFBP-1
levels are associated with T1D and related DN.
Methods
Subjects
This is a case–control study. In total, 778 Swedish subjects
were enrolled, consisting of 536 T1D patients (304 male/
232 female) as diabetic cases and 242 men with normal
glucose tolerance (NGT). According to the World Health
Organization criteria [27], all patients with T1D were diag-
nosed before 31 years of age. The duration of T1D was
more than 10 years. The NGT subjects were selected from
Stockholm Diabetes Prevention Programs (SDPP), as de-
scribed previously [19].
Clinical characteristics of all subjects with NGT or
T1D were summarized in the Additional file 1: Table S1.
Urinary AER, 20 to 200 μg/min in at least two consecutive
overnight samples was considered microalbuminuria,
whereas AER > 200 μg/min in at least two consecutive
overnight samples was considered macroalbuminuria. The
51 (25 male/26 female) T1D subjects with macroalbumi-
nuria were classified as the cases of T1D with DN, includ-
ing two T1D patients who received renal-replacement
therapy, whereas 296 (160 male/136 female) T1D patients
with persistent normal albuminuria were grouped as the
controls of T1D without DN. In addition, 189 (119 male/
70 female) T1D patients with normal albuminuria or
historic microalbuminuria had medical treatments with
angiotensin-converting-enzyme inhibitor (ACEI)/angiotensin
II-receptor blockers (ARBs). We excluded these 189 pa-
tients when we performed comparison analyses between
T1D patients with DN and those without DN. Clinical
characteristics of all T1D patients with or without DN are
represented in Additional file 2: Table S2.Informed consent was obtained from all subjects, and
the study was approved by the ethics committee of the
Karolinska Institutet, Stockholm, Sweden.
Serum IGFBP-1 and IGF-1 measurements
Serum samples were collected from all T1D subjects be-
tween 10 AM and 3 PM, and fasting serum samples
were collected from NGT subjects. All serum samples
were saved at −80°C until measurements. We used an
in-house RIA, as described previously, to measure serum
IGFBP-1 levels [12]. The sensitivity was 3 μg/L, and the
intra- and interassay CVs were 3% and 10%, respectively.
We also measured total serum IGF-1 levels with another
in-house RIA after the separation of IGFs from IGFBPs
by acid ethanol extraction and cryoprecipitation [28]. To
minimize the interference of remaining IGFBPs, des
[1-3] IGF-1 was used as a tracer. The intra- and interas-
say CVs were 4% and 11%, respectively.
DNA methylation analysis of IGFBP1
Genomic DNA was extracted from peripheral blood sam-
ples in all subjects. We used the same bisulfite pyrose-
quencing protocol as recently described in our epigenetic
study of the IGFBP1 gene in T2D [19]. This protocol has
been widely used for sensitive and quantitative universal
pyrosequencing methylation analysis of CpG sites [29].
DNA methylation levels at six CpG sites at 5′-UTR of the
IGFBP1 gene were determined by using PyroMark CpG
assay (ENSG00000146678), a PyroMark PCR kit (Qiagen,
Hilden, Germany) and PyroMark Q96 ID pyrosequencing
system (Biotage, Uppsala, Sweden). To control the conver-
sion efficiency of the bisulfite treatment and accuracy in
methylation analyses, unmethylated bisulfite converted
and unconverted DNA samples (Qiagen) were used.
Statistical analyses
All data were analyzed by using PASW statistics program
(SPSS 20.0; Chicago, IL, USA). Data presented in the
tables and figures are either mean with 95% confidence
interval (CI) or geometric mean with 95% CI if the data
were not normally distributed. Continuous variables be-
tween groups were compared by using an unpaired t test
or one-way ANOVA followed with Tukey post hoc
test. Covariate-adjusted generalized linear models were
used when adjusting for age. Linear regression analyses
were used to examine the relation between variables.
P values < 0.05 were considered statistically significant.
Additional files
Additional file 1: Table S1. Clinical characteristics of Swedish subjects
with normal glucose tolerance and type 1 diabetes.
Additional file 2: Table S2. Clinical characteristics of Swedish type 1
diabetes patients with and without diabetic nephropathy.
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